Adjuvant Chemotherapy for Node Negative, High Recurrence ScoreTM Breast Cancer: In Defense of De-Escalation

npj Breast Cancer - United Kingdom
doi 10.1038/s41523-019-0119-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2013English

Adjuvant Chemotherapy for Early Breast Cancer.

BMJ
1983English

Node Negative Breast Cancer.

BMJ
1990English

Cost Effectiveness of Molecular Profiling for Adjuvant Decision Making in Patients With Node-Negative Breast Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2014English

Progress in Adjuvant Chemotherapy for Breast Cancer: An Overview

BMC Medicine
Medicine
2015English

Towards De-Escalation of Axillary Management After Neoadjuvant Chemotherapy in Breast Cancer

English

Randomised Trial: Survival Benefit and Safety of Adjuvant Dose-Dense Chemotherapy for Node-Positive Breast Cancer

British Journal of Cancer
Cancer ResearchOncology
2006English

Adjuvant Chemotherapy and Trastuzumab Is Safe and Effective in Older Women With Small, Node-Negative, HER2-Positive Early-Stage Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2016English

Leucocyte Nadir as a Marker for Chemotherapy Efficacy in Node-Positive Breast Cancer Treated With Adjuvant CMF

British Journal of Cancer
Cancer ResearchOncology
1999English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy